FAK is an emerging target in cancer therapies, due to its probable role in tumor metastasis.42 However, FAK inhibitors only have modest clinical activity in the clinical trials, and now many efforts are focused on exploring efficient combinational therapies.41 As expected, concurrent inhibition of FAK by FAK specific inhibitor defactinib reversed HDAC inhibitor-induced breast cancer metastasis. Here, HDAC9 is linked to breast cancer.